- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | SIRNAOMICS-B (02257): (1) GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS AND (2) CONDITIONAL GRANT OF RESTRICTED SHARE UNITS TO A DIRECTOR | - | HKEx | ||
| 12.10. | Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 | 703 | VASRO GmbH | VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company's announcement of 6 October 2026 and the FDA's written responses of 10 September. A state-owned fund, Guangzhou... ► Artikel lesen | |
| 06.10. | SIRNAOMICS-B (02257): DISCLOSEABLE TRANSACTION SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY AND GRANT OF ... | 1 | HKEx | ||
| 07.09. | Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY | 733 | VASRO GmbH | VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share. Sirnaomics develops siRNA medicines, drugs that silence a disease-causing... ► Artikel lesen | |
| 03.09. | SIRNAOMICS-B (02257): INTERIM REPORT 2026 | 1 | HKEx | ||
| 28.08. | SIRNAOMICS-B (02257): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| SIRNAOMICS Aktie jetzt für 0€ handeln | |||||
| 26.08. | SIRNAOMICS-B (02257): DISCLOSEABLE TRANSACTION - DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY AND GRANT OF REPURCHASE RIGHT | 2 | HKEx | ||
| 14.08. | SIRNAOMICS-B (02257): INSIDE INFORMATION - ISSUE OF A WRIT OF SUMMONS | 2 | HKEx | ||
| 14.08. | SIRNAOMICS-B (02257): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 12.08. | SIRNAOMICS-B (02257): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 12.08. | SIRNAOMICS-B (02257): COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 30.07. | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE II CLINICAL TRIAL OF STP705 FOR MEDICAL AESTHETIC | - | HKEx | ||
| 21.07. | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - ESTABLISHMENT OF EXTERNAL SCIENTIFIC ADVISORY BOARD | - | HKEx | ||
| 30.06. | SIRNAOMICS-B (02257): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, JUNE 30, 2026 | - | HKEx | ||
| 24.06. | SIRNAOMICS-B (02257): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING IN THE COMPANY BY A DIRECTOR | - | HKEx | ||
| 23.06. | SIRNAOMICS-B (02257): SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 23.06. | SIRNAOMICS-B (02257): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 23, 2026 AND AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION | - | HKEx | ||
| 12.06. | SIRNAOMICS-B (02257): PROXY FORM | - | HKEx | ||
| 12.06. | SIRNAOMICS-B (02257): 1. PROPOSED TERMINATION OF THE 2022 RSU SCHEME AND PROPOSED ADOPTION OF THE 2026 RSU SCHEME AND 2. PROPOSED TERMINATION OF THE 2022 ... | - | HKEx | ||
| 12.06. | SIRNAOMICS-B (02257): NOTICE OF EXTRAORDINARY GENERAL MEETING | - | HKEx |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,120 | -0,19 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,34 | +13,15 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| MODERNA | 248,10 | +8,94 % | G Sachs Raises Moderna, Inc. TP to USD195 as Oncology Business Momentum Strengthens | ||
| SUMMIT THERAPEUTICS | 17,780 | +8,75 % | Stifel cuts Summit Therapeutics stock price target on valuation | ||
| IMMUNOVANT | 33,860 | +10,98 % | Roivant outlines Investor Day focus as IMVT-1402 targets 85,000 difficult-to-treat RA patients | ||
| EDGEWISE THERAPEUTICS | 46,360 | +2,95 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 13,890 | +13,85 % | Vir Biotechnology: HDV-Daten lassen Aktie explodieren | Vir Biotechnology sorgt mit gleich zwei positiven Nachrichten im Bereich Hepatitis Delta für Aufsehen. Sowohl die ersten Ergebnisse der zulassungsrelevanten Phase-3-Studie als auch erweiterte Phase-2-Daten... ► Artikel lesen | |
| EDESA BIOTECH | 2,900 | +34,88 % | Edesa Biotech Stock Jumps 39% On Japan Licensing Deal | ||
| KINIKSA PHARMACEUTICALS | 98,13 | +4,55 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,785 | +7,68 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? | ||
| KYMERA THERAPEUTICS | 136,27 | +3,46 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| ERASCA | 15,170 | +5,27 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EVOTEC | 3,142 | -0,70 % | Ihre wichtigsten Termine: Heute im Fokus: Rheinmetall, Cloudflare, MP Materials, Airbnb, Lyft und Telekom | © Foto: Julian Stratenschulte/dpa Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte:... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,325 | +6,70 % | Morning Market Movers: Curis, Inc., Darkiris, Amdocs, Nurix Therapeutics See Big Swings | NICOSIA (dpa-AFX) - At 8:05 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| JANUX THERAPEUTICS | 13,930 | -21,08 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 |
Das Unternehmen SIRNAOMICS LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,450 Euro und damit +0,90 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIRNAOMICS LTD finden Sie auf Wallstreet Online.